Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.49 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 5/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128614 | 1.00 | KDM4E (0.49) | KDM4ECSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL29686936 | 0.86 | CHRNB2 (0.44) | KDM4ECHRNB2CHRNA4MAPTNPC1 | |
| SCHEMBL17749939 | 0.84 | ALDH1A1 (0.44) | KDM4ECHRNB2CHRNA4L3MBTL1HSD17B10 | |
| SCHEMBL6281582 | 0.80 | HTT (0.50) | KDM4ECHRNB2CHRNA4TDP1L3MBTL1 | |
| SCHEMBL11248491 | 0.78 | GPR35 (0.57) | KDM4ECHRNB2CHRNA4TDP1L3MBTL1 | |
| SCHEMBL24776512 | 0.78 | MEN1 (0.40) | USP2CHRNB2CHRNA4HSD17B10MAPT | |
| SCHEMBL24620866 | 0.77 | F7 (0.46) | KDM4EUSP2PIM1PIM2L3MBTL1 | |
| SCHEMBL30973431 | 0.75 | PIM1 (0.42) | KDM4ECSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL31429009 | 0.75 | RAB9A (0.52) | KDM4EL3MBTL1HSD17B10MAPTHPGD | |
| SCHEMBL10513311 | 0.74 | CA2 (0.54) | CHRNB2CHRNA4HPGDHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324772-A | Synthesis method and intermediate of furan [3,2-b ] pyridine derivative | 北京颖诺凯胜科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-118324772-A | Synthesis method and intermediate of furan [3,2-b ] pyridine derivative | 北京颖诺凯胜科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118324772-A | Synthesis method and intermediate of furan [3,2-b ] pyridine derivative | 北京颖诺凯胜科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11597728-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-07 | — | — | US | disclosed |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| EP-4007758-A1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | Mersana Therapeutics, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885CSNK2A1 1260/4885CSNK2A2 1047/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885CSNK2A1 1260/4885CSNK2A2 1047/4885 |
| US-11597728-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885CSNK2A1 1260/4885CSNK2A2 1047/4885 |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885CSNK2A1 1260/4885CSNK2A2 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.